Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coiled-coil domain-containing protein 138 is a soluble nuclear protein, predominantly expressed at low levels across most tissues, but upregulated in certain cancer contexts, especially UCEC. It is implicated in centrosome integrity, ciliary assembly, and regulation of key oncogenic pathways (mTOR, p53/Rb, MYC/MYCN). Knockdown experiments demonstrate reduced cellular proliferation and altered gene expression in cancer cell lines, supporting its oncogenic role. CCDC138 interacts with proteins central to microtubule dynamics and ciliogenesis, but has no well-defined enzymatic or receptor activity. The protein contains a conserved leucine zipper, is subject to extensive phosphorylation and sumoylation, and exists in at least two isoforms. Its dual associations with ciliary biology and oncogenic signaling mark it as a promising biomarker and candidate therapeutic target in cancer, while also hinting at possible roles in ciliopathies.
Not specifically established; knockdown reduces cell proliferation, downregulates mTOR, S6K1, and p21 (suggesting drugs targeting mTOR pathway may be more effective in CCDC138-high tumors)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coiled-coil domain-containing protein 138 (CCDC138).